دورية أكاديمية
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
| العنوان: | Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial. |
|---|---|
| المؤلفون: | Cooke SA; Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands., Belderbos JSA; Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands. Electronic address: J.belderbos@nki.nl., Reymen B; Department of Radiation Oncology (MAASTRO Clinic), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Lambrecht M; Department of Oncology, Experimental Radiation Oncology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Radiotherapy-Oncology, University Hospitals Leuven, Gasthuisberg, Belgium., Fredberg Persson G; Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Faivre-Finn C; Department of Clinical Oncology, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK., Dieleman EMT; Department of Radiation Oncology, Location AMC, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., van Diessen JNA; Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands., Sonke JJ; Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands., de Ruysscher D; Department of Radiation Oncology (MAASTRO Clinic), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands. |
| المصدر: | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Jul; Vol. 196, pp. 110312. Date of Electronic Publication: 2024 Apr 24. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Limerick : Elsevier Scientific Publishers Original Publication: Amsterdam : Elsevier Science Publishers, c1983- |
| مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/radiotherapy , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/radiotherapy , Lung Neoplasms*/pathology , Patient Reported Outcome Measures* , Quality of Life*, Humans ; Male ; Female ; Middle Aged ; Aged ; Neoplasm Staging ; Radiotherapy Dosage ; Chemoradiotherapy/adverse effects ; Positron-Emission Tomography |
| مستخلص: | Background and Purpose: The ultimate challenge in dose-escalation trials lies in finding the balance between benefit and toxicity. We examined patient-reported outcomes (PROs), including health-related quality of life (HRQoL) in patients with locally advanced non-small cell lung cancer (LA-NSCLC), treated with dose-escalated radiotherapy. Materials and Methods: The international, randomised, phase 2 ARTFORCE PET-Boost study (NCT01024829) aimed to improve 1-year freedom from local failure rates in patients with stage II-III NSCLC, with a ≥ 4 cm primary tumour. Treatment consisted of an individualised, escalated fraction dose, either to the primary tumour as a whole or to its most FDG-avid subvolume (24 x 3.0-5.4 Gy). Patients received sequential or concurrent chemoradiotherapy, or radiotherapy only. Patients were asked to complete the EORTC QLQ-C30, QLQ-LC13, and the EuroQol-5D at eight timepoints. We assessed the effect of dose-escalation on C30 sum score through mixed-modelling and evaluated clinically meaningful changes for all outcomes. Results: Between Apr-2010 and Sep-2017, 107 patients were randomised; 102 were included in the current analysis. Compliance rates: baseline 86.3%, 3-months 85.3%, 12-months 80.3%; lowest during radiation treatment 35.0%. A linear mixed-effect (LME) model revealed no significant change in overall HRQoL over time, and no significant difference between the two treatment groups. Physical functioning showed a gradual decline in both groups during treatment and at 18-months follow-up, while clinically meaningful worsening of dyspnoea was seen mainly at 3- and 6-months. Conclusion: In patients with LA-NSCLC treated with two dose-escalation strategies, the average patient-reported HRQoL remained stable in both groups, despite frequent patient-reported symptoms, including dyspnoea, dysphagia, and fatigue. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Carcinoma, non-small-cell-lung; Carcinoma, non-small-cell-lung / Radiotherapy; Clinical trials; Patient reported outcome measures*; Quality of life*; Radiotherapy dosage |
| تواريخ الأحداث: | Date Created: 20240425 Date Completed: 20240609 Latest Revision: 20240609 |
| رمز التحديث: | 20240610 |
| DOI: | 10.1016/j.radonc.2024.110312 |
| PMID: | 38663582 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0887 |
|---|---|
| DOI: | 10.1016/j.radonc.2024.110312 |